Literature DB >> 30851228

Cholangiocarcinoma: Epidemiology and risk factors.

Shahid A Khan1, Simona Tavolari2, Giovanni Brandi3,4.   

Abstract

Cholangiocarcinoma (CCA) is a heterogeneous disease arising from a complex interaction between host-specific genetic background and multiple risk factors. Globally, CCA incidence rates exhibit geographical variation, with much higher incidence in parts of the Eastern world compared to the West. These differences are likely to reflect differences in geographical risk factors as well as genetic determinants. Of note, over the past few decades, the incidence rates of CCA appear to change and subtypes of CCA appear to show distinct epidemiological trends. These trends need to be interpreted with caution given the issues of diagnosis, recording and coding of subtypes of CCA. Epidemiological evidences suggest that in general population some risk factors are less frequent but associated with a higher CCA risk, while others are more common but associated with a lower risk. Moreover, while some risk factors are shared by intrahepatic and both extrahepatic forms, others seem more specific for one of the two forms. Currently some pathological conditions have been clearly associated with CCA development, and other conditions are emerging; however, while their impact in increasing CCA risk as single etiological factors has been provided in many studies, less is known when two or more risk factors co-occur in the same patient. Moreover, despite the advancements in the knowledge of CCA aetiology, in Western countries about 50% of cases are still diagnosed without any identifiable risk factor. It is therefore conceivable that other still undefined etiologic factors are responsible for the recent increase of CCA (especially iCCA) incidence worldwide.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cholangiocarcinoma; epidemiology; misclassification; risk factors

Mesh:

Year:  2019        PMID: 30851228     DOI: 10.1111/liv.14095

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  122 in total

1.  68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Authors:  Rita Chahinian; Ahmad El-Amine; Sayed Matar; Mostafa Annan; Ali Shamseddine; Mohamad Haidar
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

Review 2.  How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giorgio Frega; Andrea Palloni; Stefania DE Lorenzo; Francesca Abbati; Veronica Mollica; Simona Tavolari; Mariacristina DI Marco; Giovanni Brandi
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

4.  Incidence and Prognosis of Biliary Tract and Gallbladder Cancers in a Belgian Academic Hospital.

Authors:  Quentin Gilliaux; Laurence Faugeras; Jean-Paul Martinet; Thierry De Ronde; Abdenor Badaoui; Claude Bertrand; Alexandra Dili; Monique Delos; Jacques Jamart; Axel Baily; Lionel D'Hondt
Journal:  J Gastrointest Cancer       Date:  2020-09-28

Review 5.  Meta-analysis of laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma.

Authors:  Nikolaos Machairas; Ioannis D Kostakis; Dimitrios Schizas; Stylianos Kykalos; Nikolaos Nikiteas; Georgios C Sotiropoulos
Journal:  Updates Surg       Date:  2020-11-21

Review 6.  Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Simona Tavolari; Giovanni Brandi
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 7.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

8.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

9.  Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Gun Ha Kim; Pyeong Hwa Kim; Jin Hyoung Kim; Pyo-Nyun Kim; Hyung Jin Won; Yong Moon Shin; Sang Hyun Choi
Journal:  Eur Radiol       Date:  2021-08-04       Impact factor: 5.315

10.  Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway.

Authors:  Sutthiwan Janthamala; Apinya Jusakul; Sarinya Kongpetch; Phongsaran Kimawaha; Poramate Klanrit; Watcharin Loilome; Nisana Namwat; Anchalee Techasen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-20       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.